Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
A concise guide to planning Social Security timing from a 30s perspective, covering factors that affect when to start and how it influences lifetime benefits.
20,404 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Asana appoints veteran tech executive Dan Rogers as CEO and highlights that breaking into Silicon Valley has always b...
As 2025 closes, KLX Energy Services faces a choppy energy market. This guide breaks down the Q4 2025 earnings landsca...
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
A sharp 20% plunge in Circle tokens sparked by yield shifts under a new Clarity Act framework. This morning minute re...
As investors retire or near retirement, the tax treatment of dividend income matters as much as the yield. This expla...
As brookfield corp's next earnings approaches, investors weigh how the company will navigate its diverse asset mix. T...
Elon Musk touched down in Beijing as the OpenAI trial with Sam Altman reaches its closing phase. A California judge w...
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
A wave of brokerage consolidation is reshaping the 2026 housing market. Industry leaders insist consolidation isn’t c...
JPMorgan's JEPI ETF offers a compelling income stream through covered calls on a diversified 110-name portfolio. This...
A 60-year-old who converted $400,000 to a Roth IRA in 2025 plans a $50,000 withdrawal in 2026, only to confront two s...